Cargando…

Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients

BACKGROUND: Antibodies against programmed death 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1) have recently shown promising results in gastric cancer (GC). However, clinicians still lack predictive biomarkers for the efficacy of anti-PD-1 therapy; thus, we investigated the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xinhua, Zhang, Huimin, Wang, Minghao, Liu, Hao, Hu, Yanfeng, Lin, Tian, Chen, Hao, Zhao, Mingli, Chen, Tao, Li, Guoxin, Yu, Jiang, Zhao, Liying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990248/ https://www.ncbi.nlm.nih.gov/pubmed/35401534 http://dx.doi.org/10.3389/fimmu.2022.783695

Ejemplares similares

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients
por: Chen, Xinhua, et al.
Publicado: (2023)

Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases
por: Liang, Huayuan, et al.
Publicado: (2022)

Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers
por: Yang, Jia, et al.
Publicado: (2023)

Application value of overlap guiding tube (OGT) in assisting overlap esophagojejunostomy during laparoscopic total gastrectomy for gastric/gastroesophageal junction (G/GEJ) tumors
por: Xinhua, Chen, et al.
Publicado: (2022)

Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study
por: Su, Jin, et al.
Publicado: (2022)

Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study
por: Liang, Yanrui, et al.
Publicado: (2021)

Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study
por: Liang, Yanrui, et al.
Publicado: (2021)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer
por: Huang, Ziling, et al.
Publicado: (2021)

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells
por: Wang, Qianqian, et al.
Publicado: (2022)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Programmed cell death and lipid metabolism of macrophages in NAFLD
por: Xiao, Zhun, et al.
Publicado: (2023)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Corrigendum: Programmed cell death and lipid metabolism of macrophages in NAFLD
por: Xiao, Zhun, et al.
Publicado: (2023)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Frequency and Prognosis of Pulmonary Metastases in Newly Diagnosed Gastric Cancer
por: Sun, Zepang, et al.
Publicado: (2019)

Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15–year single-institution experience
por: Chen, Xinhua, et al.
Publicado: (2022)

Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma
por: Cui, Yong-Xin, et al.
Publicado: (2020)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Enhanced recovery after surgery in laparoscopic distal gastrectomy: Protocol for a prospective single-arm clinical trial
por: Chen, Xinhua, et al.
Publicado: (2021)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Promotion of Cell Proliferation through Inhibition of Cell Autophagy Signalling Pathway by Rab3IP is Restrained by MicroRNA-532-3p in Gastric Cancer
por: Guo, Weihong, et al.
Publicado: (2018)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Clinicopathological Significance of NMIIA Overexpression in Human Gastric Cancer
por: Liu, Dongning, et al.
Publicado: (2012)

Liver Metastases in Newly Diagnosed Gastric Cancer: A Population-Based Study from SEER
por: Sun, Zepang, et al.
Publicado: (2019)

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score‐matched analysis
por: Geng, Xiuwen, et al.
Publicado: (2016)

Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
por: Peña-Cardelles, Juan Francisco, et al.
Publicado: (2022)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
por: Zheng, Hao, et al.
Publicado: (2022)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Genomics Score Based on Genome-Wide Network Analysis for Prediction of Survival in Gastric Cancer: A Novel Prognostic Signature
por: Sun, Zepang, et al.
Publicado: (2020)

Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
por: Gao, Hengxing, et al.
Publicado: (2023)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity
por: Zheng, Hao, et al.
Publicado: (2022)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures
por: Lin, Ziying, et al.
Publicado: (2016)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
por: Ding, Xing-Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j1qk4sc96jdtesagtl1g9s59t0